• 1. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

Comprehensive Overview of Cytochalasin J (CAS No. 53760-20-6): Mechanism, Applications, and Research Insights

Cytochalasin J (CAS No. 53760-20-6) is a naturally occurring fungal metabolite belonging to the cytochalasin family, a group of compounds renowned for their ability to disrupt actin polymerization in eukaryotic cells. This unique property has made Cytochalasin J a valuable tool in cell biology research, particularly in studies involving cytoskeletal dynamics, cell motility, and intracellular transport. Researchers frequently search for "Cytochalasin J mechanism of action" or "Cytochalasin J vs. Cytochalasin D" to understand its comparative advantages in experimental settings.

The structural uniqueness of Cytochalasin J lies in its macrocyclic ring fused to an indole moiety, which distinguishes it from other cytochalasin derivatives. Recent studies highlight its potential in modulating cellular processes like cytokinesis and endocytosis, sparking interest in queries such as "Cytochalasin J cell division inhibition" and "applications of Cytochalasin J in cancer research." Its selective actin-binding capacity also makes it a candidate for investigating neurodegenerative diseases linked to cytoskeletal dysfunction.

In the context of modern biotechnology, Cytochalasin J has gained attention for its role in organoid development and 3D cell culture models. Scientists exploring "how to use Cytochalasin J in stem cell studies" often leverage its ability to reversibly alter cell morphology without inducing apoptosis. This reversible effect is critical for applications requiring temporary cytoskeletal disruption, such as in vitro fertilization (IVF) research or tissue engineering.

From a pharmacological perspective, Cytochalasin J exhibits lower cytotoxicity compared to other cytochalasins, as evidenced by searches for "Cytochalasin J toxicity profile." This characteristic expands its utility in long-duration experiments where cell viability is paramount. Additionally, its interactions with G-actin have been scrutinized in structural biology, with cryo-EM studies revealing atomic-level insights into actin filament destabilization.

Emerging trends show growing interest in "natural sources of Cytochalasin J" and "synthetic pathways for Cytochalasin J production," reflecting demands for sustainable sourcing and scalable synthesis. The compound’s stability under physiological conditions also makes it a candidate for drug delivery system studies, particularly in targeting cytoskeleton-dependent processes in pathological cells.

In summary, Cytochalasin J (CAS No. 53760-20-6) remains a cornerstone reagent in cytoskeleton research, with evolving applications in regenerative medicine and disease modeling. Its nuanced effects on actin dynamics continue to inspire investigations into "Cytochalasin J as a pharmacological probe" and "next-generation cytochalasin analogs," positioning it at the forefront of interdisciplinary biomedical research.

• 56144-22-0(Cytochalasin J)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)